The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis.
Kuan-Sheng WuPei-Chin LinYao-Shen ChenTzu-Cheng PanPei-Ling TangPublished in: Annals of medicine (2021)
The use of statins was significantly associated with a reduced need for IMV and decreased mortality among individuals with COVID-19. Statins may not need to be discontinued because of concern for COVID-19 on admission. Further randomized controlled trial (RCTs) are needed to clarify the causal effect between statin use and severe COVID-19 outcomes.Key messagesParticipants in five types of studies were shown to have even lower odds of death when taking statins.The use of statins was significantly associated with a reduced need for invasive mechanical ventilation and decreased all-cause mortality among individuals with COVID-19. However, statin use did not prevent participants from needing care in the intensive care unit.The results justify performing randomized controlled trials (RCTs) to validate the benefits of statins on COVID-19 outcomes.
Keyphrases
- coronavirus disease
- sars cov
- cardiovascular disease
- randomized controlled trial
- mechanical ventilation
- cardiovascular events
- healthcare
- coronary artery disease
- emergency department
- respiratory syndrome coronavirus
- type diabetes
- intensive care unit
- palliative care
- study protocol
- risk factors
- clinical trial
- early onset
- insulin resistance
- chronic pain
- weight loss
- extracorporeal membrane oxygenation
- affordable care act